Needham Initiates Coverage On Duolingo with Buy Rating, Announces Price Target of $115
Needham analyst Ryan MacDonald initiates coverage on Duolingo (NASDAQ:DUOL) with a Buy rating and announces Price Target of $115.
RBC Capital Upgrades Cerence to Sector Perform, Lowers Price Target to $27
RBC Capital analyst Joseph Spak upgrades Cerence (NASDAQ:CRNC) from Underperform to Sector Perform and lowers the price target from $28 to $27.
Needham Initiates Coverage On GitLab with Buy Rating, Announces Price Target of $70
Needham analyst Mike Cikos initiates coverage on GitLab (NASDAQ:GTLB) with a Buy rating and announces Price Target of $70.
Chardan Capital Initiates Coverage On EyePoint Pharmaceuticals with Buy Rating, Announces Price Target of $21
Chardan Capital analyst Daniil Gataulin initiates coverage on EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy rating and announces Price Target of $21.
Citigroup Downgrades Consolidated Comms Hldgs to Sell, Announces $5 Price Target
Citigroup analyst Michael Rollins downgrades Consolidated Comms Hldgs (NASDAQ:CNSL) from Neutral to Sell and announces $5 price target.
Mizuho Initiates Coverage On BioXcel Therapeutics with Buy Rating, Announces Price Target of $19
Mizuho analyst Graig Suvannavejh initiates coverage on BioXcel Therapeutics (NASDAQ:BTAI) with a Buy rating and announces Price Target of $19.
Mizuho Initiates Coverage On Athira Pharma with Buy Rating, Announces Price Target of $6
Mizuho analyst Graig Suvannavejh initiates coverage on Athira Pharma (NASDAQ:ATHA) with a Buy rating and announces Price Target of $6.
Mizuho Initiates Coverage On Alector with Buy Rating, Announces Price Target of $15
Mizuho analyst Graig Suvannavejh initiates coverage on Alector (NASDAQ:ALEC) with a Buy rating and announces Price Target of $15.
Wells Fargo Downgrades Bank OZK to Equal-Weight, Lowers Price Target to $42
Wells Fargo analyst Jared Shaw downgrades Bank OZK (NASDAQ:OZK) from Overweight to Equal-Weight and lowers the price target from $58 to $42.
Mizuho Initiates Coverage On Cerevel Therapeutics Hldg with Neutral Rating, Announces Price Target of $30
Mizuho analyst Graig Suvannavejh initiates coverage on Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Neutral rating and announces Price Target of $30.